DoD and NIH search independently for AIDS vaccine

WASHINGTON - The Department of Defense and NIH are moving on separate tracks to develop therapeutic AIDS vaccines in the aftermath of DoD's decision to reallocate $20 million that had been earmarked for a Phase III trial of MicroGeneSys Inc.'s VaxSyn gp160 vaccine.

The U.S. Army Medical Research and Development Command (USAMRDC) is seeking proposals for grants to support HIV vaccine development with an emphasis on therapeutic vaccines. The proposals should be for two- to four-year research in the basic sciences, preclinical, or clinical areas and should focus on novel approaches and unique immunogens...